awmsg logo



etravirine (Intelence®)


Reference No. 1683

Publication date:
13/12/2013


Last review date:
01/12/2016

Appraisal information

etravirine (Intelence®) 200 mg tablet
etravirine (Intelence®) 25 mg tablet
etravirine (Intelence®) 100 mg tablet


Company: Janssen-Cilag Ltd
BNF category: Infections
NMG meeting date: 23/10/2013
AWMSG meeting date: 20/11/2013
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 3213
Ministerial ratification: 06/12/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Etravirine (Intelence®) is recommended as an option for use within NHS Wales, in combination with a boosted protease inhibitor and other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced paediatric patients from 6 years to less than 18 years of age.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download